Adipotide is the black sheep of weight-loss peptides. Where GLP-1 drugs like semaglutide work gently — nudging appetite and slowing the stomach — adipotide does something blunt and dramatic: it kills the blood vessels that feed body fat, so the fat is starved and reabsorbed. In obese monkeys the results were striking. But the same studies flagged a kidney problem, and two decades on it has never become a medicine. It is also called FTPP (fat-targeted proapoptotic peptide).
In plain terms: most weight drugs ask your body to eat less; adipotide tries to cut off fat's supply lines.
What it is
Adipotide is a ligand-directed peptidomimetic — a two-part designer peptide (full sequence CKGGRAKDC-GG-(D)(KLAKLAK)₂)2. One part is a homing tag (CKGGRAKDC) that seeks out a protein called prohibitin on the surface of the blood vessels that supply white fat. The other part is a proapoptotic peptide — a short sequence that triggers apoptosis, or programmed cell death. Bolt them together and you get a molecule that travels to fat's blood vessels and kills them.
How it is thought to work
The idea came from a 2004 mouse study. Using a technique called in vivo phage display, researchers found a peptide (CKGGRAKDC) that homes specifically to the blood vessels of white fat, and showed it binds prohibitin — a protein that acts as a kind of postcode for adipose-tissue blood vessels1. Attach a cell-killing peptide to that postcode, and you selectively destroy the vessels feeding fat. Starved of blood, the fat deposits are resorbed. In mice this caused "rapid obesity reversal" with no obvious adverse effects1.
In plain terms: fat needs a blood supply like any tissue. Adipotide targets that supply and shuts it down.
This is a fundamentally different lever from every approved obesity drug — which is why it drew attention, and why its risks are different too.
What the studies actually found
Adipotide's evidence base is small and, importantly, entirely in animals. Note the model in each row.
| Study | Model | Key result | Year |
|---|---|---|---|
| Kolonin et al.1 | obese mice | Targeting a proapoptotic peptide to prohibitin ablated white fat and reversed obesity, reportedly without detectable adverse effects | 2004 |
| Barnhart et al.2 | obese Old World monkeys | Adipotide caused rapid weight loss and improved insulin resistance (confirmed by MRI and DXA) — but monkeys showed dose-dependent changes in kidney (renal proximal tubule) function | 2011 |
| Criscione — commentary3 | critique of the monkey study | Argued the weight loss "may instead reflect a direct effect of adipotide on food consumption" — i.e., reduced eating, not only vessel ablation | 2012 |
The monkey study is the headline everyone cites: rapid weight loss and better insulin sensitivity in obese primates2. But read the same abstract to the end and the catch is in the authors' own words — at effective doses, monkeys from three species showed "predictable and reversible changes in renal proximal tubule function"2. The kidneys felt it.
The catches — why it stalled
Three honest problems sit between adipotide and a real medicine:
- The kidney signal. The very study that made adipotide famous reported dose-dependent renal-tubule changes in monkeys2. A compound that only reaches effective doses alongside kidney effects has a narrow safety margin.
- What actually drove the weight loss? A published commentary argued the loss might partly reflect adipotide making the monkeys eat less, rather than the elegant blood-vessel mechanism alone3. If so, the headline mechanism is doing less of the work than it appears.
- No human proof. More than twenty years after the mouse work, and over a decade after the monkeys, the pivotal efficacy evidence is still animal. Adipotide is not an approved medicine and has no established human weight-loss data.
Regulatory status
Adipotide is not an approved medicine and is not in clinical use for obesity. It is an experimental compound whose efficacy has been shown in animals only. This page explains what it is and what the studies showed — not how to use it — and it takes no position on sourcing.
The short version
Adipotide (FTPP) is a two-part peptide that homes to the blood vessels of white fat (via prohibitin) and kills them, starving fat of its blood supply. In obese mice and monkeys it produced dramatic weight loss — but the monkey study also reported reversible kidney-tubule changes, a commentary questioned how much of the effect was simply reduced eating, and there is still no approved human use. It's a genuinely novel idea with a genuinely unresolved safety question. For an approved, appetite-based alternative see semaglutide; for another honestly-mixed fat-loss peptide see AOD-9604. Educational overview only, not medical advice.